The EXHALE Pilot
Research type
Research Study
Full title
A cross-sectional, feasibility study to explore the use of a new device (Inflammacheck™) in measuring the level of Exhaled Breath Condensate Hydrogen Peroxide (EBC H2O2) in patients with Asthma, COPD, and healthy volunteers. The EXHALE Pilot. EXhaled Hydrogen peroxide As a marker of Lung diseasE (EXHALE) Pilot.
IRAS ID
214218
Contact name
Anoop Chauhan
Contact email
Sponsor organisation
Portsmouth Hospitals NHS Trust
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are common lung conditions that affect over 6 million people in the UK. There are still many people who remain undiagnosed and suffer as a result. Attacks (or 'exacerbations') of asthma and COPD can be difficult to detect and treat quickly, resulting in frequent hospital admissions.
We know airway inflammation is a feature of asthma and COPD and can be used to help diagnose these conditions. Current ways of assessing airway inflammation can be invasive or difficult for patients to complete. ‘Inflammacheck’ is a novel, non-invasive breathing test that collects exhaled breath condensate hydrogen peroxide (EBC H202), a direct measure of airway inflammation.
We need to study 'Inflammacheck' in asthmatic and COPD patients, to see if it can consistently detect airway inflammation in these patients compared to people without lung disease and therefore be a potential diagnostic test.The Study:
Will be performed at Queen Alexandra Hospital (QAH), Portsmouth and is anticipated to last 6 months. We will recruit 30 patients with asthma, 30 with COPD and 30 healthy controls. People will be recruited from outpatient clinics. Once consented, participants will have; baseline information taken, questionnaires completed about their disease and perform standard breathing tests including the new 'Inflammacheck' test. 'Inflammacheck' is designed so that it requires a person to simply breathe into a mouthpiece at their normal, relaxed rate of breathing for around 20 breaths. Once completed, participants and HealthCare Professionals will fill in a questionnaire about their experience of the new ‘Inflammacheck’ device.
The results of this study will guide the design of larger trials to determine the use of 'Inflammacheck' in clinical practice.REC name
West Midlands - Solihull Research Ethics Committee
REC reference
16/WM/0404
Date of REC Opinion
25 Sep 2016
REC opinion
Further Information Favourable Opinion